Kinase Inhibitors Market

Kinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Oral JAK Inhibitors Hold Promising Potential for Treatment of Alopecia Areata

Kinase inhibitors are being highly publicized as a potential treatment for alopecia areata (AA). Janus kinase (JAK) inhibitors are being researched for the pathogenesis of alopecia areata, thus revealing that autoreactive cytotoxic T cells are important in the pathway that involves JAK.

Companies in the kinase inhibitors market are collaborating with researchers to carry out single-arm clinical trials, thus revealing the potential of oral JAK inhibitors as therapeutic agents for AA. Potential outcomes suggest that oral JAK inhibitors are effective and substantially tolerable to cases of moderate to severe AA. Researchers in the kinase inhibitors market are increasing efforts to conduct placebo?controlled clinical trials in order to confirm its efficacy and long-term safety.

Recent advancements are being made in anti-angiogenesis receptor tyrosine kinase inhibitors for the treatment of cancer. Angiogenesis is gaining the attention of healthcare companies to develop therapeutic targets for malignant tumors. Companies are achieving success by targeting angiogenesis in various carcinomas.

kinase inhibitors market infographic

To know the scope of our report Get a Sample on Kinase Inhibitors Market

AI Accelerates Drug Discovery for Fibrosis Treatment through Molecular Modeling

The kinase inhibitors market is expected to expand at a modest CAGR of ~4% during the forecast period. However, innovations such as AI are transforming the market for kinase inhibitors. For instance, the U.S. biotechnology startup Insilico Medicine revealed its deep learning system that is capable of identifying potential treatments for fibrosis with the help of DDR1 (Discoidin Domain Receptor 1) kinase inhibitors. 

AI is entering the kinase inhibitors market. Hence, companies should collaborate with biotechnology startups that are capable of integrating target identification with small molecule discovery through AI. Companies are increasing their efficacy in molecular modeling to accelerate drug discovery for fibrosis and other diseases.

Healthcare companies are capitalizing on generative adversarial networks (GANs) to generate novel molecular structures with specified properties. Likewise, deep learning is enabling companies with rapid identification of potent DDR1 kinase inhibitors. Thus, companies are improving their production capabilities to develop a novel drug pipeline of treatment of fibrosis with the help of AI.

Get a glimpse of the in-depth analysis through our Report Brochure

Biochemistry a Key Focus Point for Development of Novel Kinase Inhibitors

Novel assays and profiling techniques are helping companies to develop improved kinase inhibitors for drug development. Discovery of new kinase inhibitors is anticipated to improve biochemical, cellular, and in vivo assays that could offer new therapeutic targets. This is important since oncology is the focus of healthcare providers in the kinase inhibitors space, and research in this field of study is projected to grow exponentially.

Companies in the kinase inhibitors market are increasing R&D to gain expertise in cell signaling for the development of new drugs. The kinase inhibitors market is continuing to grow since the market is largely consolidated with major players accounting to ~68% of the market share. However, developing novel kinase inhibitors poses as a challenge for manufacturers. Hence, manufacturers are collaborating with researchers to acquire a decision-based understanding of kinase biology, cell signaling, and its outcome in various diseases. They are increasing efforts to gain information on biochemical and biophysical assays to examine the potency and selectivity of kinase inhibitors.

Companies Expand Product Portfolio of Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis

Tyrosine kinase inhibitors are being increasingly used for the treatment of autoimmune and inflammatory skin diseases. This is evident since inflammatory diseases application segment is estimated to account for a significant share of the kinase inhibitors market. The global kinase inhibitors market is estimated to reach a value of ~US$ 64.9 Bn by the end of 2027. Owing to excellent multiple signaling processes and disease pathogenesis of tyrosine kinase inhibitors, companies are tapping into incremental opportunities, since these inhibitors serve as novel therapeutic agents for inflammatory and other diseases.

Small molecule tyrosine kinase inhibitors are capable of acquiring pharmacological control in malignant processes, and autoimmune and immune-mediated diseases. Companies in the kinase inhibitors market are expanding their product portfolio in tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. They are increasing efforts to gain approval from health commissions for JAK inhibitors, owing to their effectiveness in the treatment of rheumatoid arthritis.

kinase inhibitors market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’  Viewpoint

Developers are designing immune-modulatory agents for single and combination therapies for the treatment of inflammatory and central nervous system disorders. Companies in the kinase inhibitors market are developing cell assays, since they are more advantageous than biochemical assays, owing to the former’s representation in physiological situation.

Multikinase inhibitors are projected for aggressive growth in the market. However, the effectiveness of multikinase inhibitors is short-lived in RET fusion-positive non-small cell lung cancer. Hence, companies should increase research to find a combination of therapeutics to prevent resistance of multikinase inhibitors toward RET-driven cancer. Companies should tap into opportunities in North America and Asia Pacific, since the kinase inhibitors market in these regions is projected for aggressive growth during the forecast period.

Kinase Inhibitors Market: Overview

  • Various types of kinase inhibitors available in the market such as non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C inhibitors, RHO kinase inhibitors, and others
  • In terms of revenue generation, the non-receptor tyrosine kinase inhibitors dominated the market. However, growth of the receptor tyrosine kinase inhibitors segment is anticipated to restrain, owing to patent expiry and introduction of generic drugs.

Kinase Inhibitors Market: Drivers

  • Increase in incidence of cancer patients among population is the major cause of growth of the global kinase inhibitors market. According to the Cancer Research UK data, around 17 million new cases of cancer were reported worldwide in 2018 and around 27.5 million new cases of cancer are likely to be reported worldwide each year by 2040.
  • Expanding indications of existing and pipeline kinase inhibitors also boost the market growth. BCR-ABL TKIs, which were earlier approved for treating CML, are now indicated for treating acute lymphoblastic leukemia (ALL) and gastrointestinal tumors. Similarly, EGFR TKIs are approved for an array of indications such as pancreatic cancer, breast cancer, and non-small cell lung cancer.

Market Segmentation: Kinase Inhibitors Market

  • Based on type, the global kinase inhibitors market has been divided into non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C Inhibitors, RHO kinase inhibitors, and others. The non-receptor tyrosine kinase inhibitors segment is further sub-segmented into Bruton's tyrosine kinase (BTK) inhibitors, BCR-ABL, Janus kinase (JAK) inhibitor, mesenchymal epithelial transition growth factor (c-MET), spleen tyrosine kinase (SYK) inhibitors, and others. Receptor tyrosine kinase is again divided into VEGFR, PDGFR, EGFR, ALK, HER2, and others.
  • In terms of application, the kinase inhibitors market has been categorized into oncology, inflammatory diseases, and others. Oncology is further divided into lung cancer, renal cell cancer, breast cancer, and others.
  • Based on distribution channel, the global kinase inhibitors market has been segmented into hospital pharmacies, independent pharmacies, and online pharmacies
  • Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with market size estimations.

Regional Overview: Kinase Inhibitors Market

  • In terms of region, the global kinase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful insights of the market which is likely to help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process

Major Players

  • The report concludes with the company profiles section that includes key information about the major players in the market
  • Leading players analyzed in the report are
    • Novartis AG,
    • Pfizer,
    • Johnson & Johnson,
    • AstraZeneca,
    • Bristol-Myers Squibb,
    • Boehringer Ingelheim International GmbH,
    • Bayer AG, F.
    • Hoffmann-La Roche Ltd, 
    • Eisai Co., Ltd
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Kinase Inhibitors Market – Segmentation

TMR’s study on the global kinase inhibitors market includes information divided into: type, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global kinase inhibitors market have been discussed in detail.

Type

 

  • Non-receptor Tyrosine Kinase Inhibitors
    • Bruton’s Tyrosine Kinase (BTK) Inhibitors
    • BCR-ABL
    • Janus Kinase (JAK) Inhibitor
    • Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • Spleen Tyrosine Kinase (SYK) Inhibitors
    • Others
  • Receptor Tyrosine Kinase Inhibitors
    • VEGFR
    • PDGFR
    • EGFR
    • ALK
    • HER2
    • Others
  • Multikinase inhibitors
  • Serine/Threonine Kinase Inhibitors
  • Protein Kinase C Inhibitors
  • RHO Kinase Inhibitors
  • Others


Application

 

  • Oncology
    • Lung Cancer
    • Renal Cell Cancer
    • Breast Cancer
    • Others
  • Inflammatory Diseases
  • Others


Distribution Channel

 

  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies


Region

 

  • North America
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of kinase inhibitors market?

Kinase inhibitors market is estimated to reach a value of ~US$ 64.9 Bn by the end of 2027

What is the anticipated CAGR of the kinase inhibitors market in the forecast period?

Kinase inhibitors market is projected to expand at a CAGR of ~4% from 2019 to 2027

What are the key driving factors for the growth of the kinase inhibitors market?

Kinase inhibitors market is driven by increase in incidence of cancer patients among population

Which region is expected to project the highest market share in the global kinase inhibitors market?

North America accounted for major share of the global kinase inhibitors market, owing to introduction of new drugs

Who are the key players in the global kinase inhibitors market?

Key players in the global kinase inhibitors market include Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb

    1.  Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Kinase Inhibitors Market

    4. Market Overview

        4.1.  Introduction & Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities 

        4.3. Porter’s Five Forces Analysis

        4.4. Global Kinase Inhibitors Market Analysis and Forecast, 2017–2027

    5. Market Outlook 

        5.1. Pipeline Analysis

        5.2. Brand Analysis

        5.3. Recent Developments In Kinase Inhibitors Research 

    6. Global Kinase Inhibitors Market Analysis and Forecasts, by Type

        6.1. Introduction & Definition

        6.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

            6.2.1. Non-receptor Tyrosine Kinase Inhibitors

                6.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

                6.2.1.2. BCR-ABL

                6.2.1.3. Janus Kinase (JAK) Inhibitor

                6.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

                6.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

                6.2.1.6. Others

            6.2.2. Receptor Tyrosine Kinase Inhibitors

                6.2.2.1. VEGFR

                6.2.2.2. PDGFR

                6.2.2.3. EGFR

                6.2.2.4. ALK

                6.2.2.5. HER2

                6.2.2.6. Others

            6.2.3. Multikinase inhibitors

            6.2.4. Serine/Threonine Kinase Inhibitors

            6.2.5. Protein Kinase C Inhibitors

            6.2.6. RHO Kinase Inhibitors

            6.2.7. Others 

        6.3. Global Kinase Inhibitors Market Attractiveness, by Type

    7. Global Kinase Inhibitors Market Analysis and Forecasts, by Application

        7.1. Introduction & Definition

        7.2. Global Kinase Inhibitors Market Value (US$) Forecast, by Application, 2017–2027

            7.2.1. Oncology

                7.2.1.1. Lung Cancer

                7.2.1.2. Renal cell cancer

                7.2.1.3. Breast Cancer

                7.2.1.4. Others

            7.2.2. Inflammatory Diseases

            7.2.3. Others 

        7.3. Global Kinase Inhibitors Market Attractiveness, by Application

    8. Global Kinase Inhibitors Market Analysis and Forecasts, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

            8.2.1. Hospital Pharmacies

            8.2.2. Independent Pharmacies

            8.2.3. Online Pharmacies

        8.3. Global Kinase Inhibitors Market Attractiveness, by Distribution Channel

    9. Global Kinase Inhibitors Market Analysis and Forecasts, by Region

        9.1. Key Findings

        9.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Global Kinase Inhibitors Market Attractiveness, by Region

    10. North America Kinase Inhibitors Market Analysis and Forecast

        10.1. Introduction

        10.2. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

            10.2.1. Non-receptor Tyrosine Kinase Inhibitors

                10.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

                10.2.1.2. BCR-ABL

                10.2.1.3. Janus Kinase (JAK) Inhibitor

                10.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

                10.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

                10.2.1.6. Others

            10.2.2. Receptor Tyrosine Kinase Inhibitors

                10.2.2.1. VEGFR

                10.2.2.2. PDGFR

                10.2.2.3. EGFR

                10.2.2.4. ALK

                10.2.2.5. HER2

                10.2.2.6. Others

            10.2.3. Multikinase inhibitors

            10.2.4. Serine/Threonine Kinase Inhibitors

            10.2.5. Protein Kinase C Inhibitors

            10.2.6. RHO Kinase Inhibitors

            10.2.7. Others 

        10.3. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

            10.3.1. Oncology

                10.3.1.1. Lung Cancer

                10.3.1.2. Renal cell cancer

                10.3.1.3. Breast Cancer

                10.3.1.4. Others

            10.3.2. Inflammatory Diseases

            10.3.3. Others

        10.4. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

            10.4.1. Hospital Pharmacies

            10.4.2. Independent Pharmacies

            10.4.3. Online Pharmacies

        10.5. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Kinase Inhibitors Market Attractiveness Analysis

            10.6.1. By Type

            10.6.2. By Application

            10.6.3. By Distribution Channel

            10.6.4. By Country 

    11. Europe Kinase Inhibitors Market Analysis and Forecast

        11.1. Introduction

        11.2. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

            11.2.1. Non-receptor Tyrosine Kinase Inhibitors

                11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

                11.2.1.2. BCR-ABL

                11.2.1.3. Janus Kinase (JAK) Inhibitor

                11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

                11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

                11.2.1.6. Others

            11.2.2. Receptor Tyrosine Kinase Inhibitors

                11.2.2.1. VEGFR

                11.2.2.2. PDGFR

                11.2.2.3. EGFR

                11.2.2.4. ALK

                11.2.2.5. HER2

                11.2.2.6. Others

            11.2.3. Multikinase inhibitors

            11.2.4. Serine/Threonine Kinase Inhibitors

            11.2.5. Protein Kinase C Inhibitors

            11.2.6. RHO Kinase Inhibitors

            11.2.7. Others 

        11.3. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

            11.3.1. Oncology

                11.3.1.1. Lung Cancer

                11.3.1.2. Renal cell cancer

                11.3.1.3. Breast Cancer

                11.3.1.4. Others

            11.3.2. Inflammatory Diseases

            11.3.3. Others

        11.4. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

            11.4.1. Hospital Pharmacies

            11.4.2. Independent Pharmacies

            11.4.3. Online Pharmacies

        11.5. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Europe Kinase Inhibitors Market Attractiveness Analysis

            11.6.1. By Type

            11.6.2. By Application

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

        12.1. Introduction

        12.2. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

            12.2.1. Non-receptor Tyrosine Kinase Inhibitors

                12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

                12.2.1.2. BCR-ABL

                12.2.1.3. Janus Kinase (JAK) Inhibitor

                12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

                12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

                12.2.1.6. Others

            12.2.2. Receptor Tyrosine Kinase Inhibitors

                12.2.2.1. VEGFR

                12.2.2.2. PDGFR

                12.2.2.3. EGFR

                12.2.2.4. ALK

                12.2.2.5. HER2

                12.2.2.6. Others

            12.2.3. Multikinase inhibitors

            12.2.4. Serine/Threonine Kinase Inhibitors

            12.2.5. Protein Kinase C Inhibitors

            12.2.6. RHO Kinase Inhibitors

            12.2.7. Others 

        12.3. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

            12.3.1. Oncology

                12.3.1.1. Lung Cancer

                12.3.1.2. Renal cell cancer

                12.3.1.3. Breast Cancer

                12.3.1.4. Others

            12.3.2. Inflammatory Diseases

            12.3.3. Others

        12.4. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

            12.4.1. Hospital Pharmacies

            12.4.2. Independent Pharmacies

            12.4.3. Online Pharmacies

        12.5. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Asia Pacific Kinase Inhibitors Market Attractiveness Analysis

            12.6.1. By Type

            12.6.2. By Application

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Kinase Inhibitors Market Analysis and Forecast

        13.1. Introduction

        13.2. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

            13.2.1. Non-receptor Tyrosine Kinase Inhibitors

                13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

                13.2.1.2. BCR-ABL

                13.2.1.3. Janus Kinase (JAK) Inhibitor

                13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

                13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

                13.2.1.6. Others

            13.2.2. Receptor Tyrosine Kinase Inhibitors

                13.2.2.1. VEGFR

                13.2.2.2. PDGFR

                13.2.2.3. EGFR

                13.2.2.4. ALK

                13.2.2.5. HER2

                13.2.2.6. Others

            13.2.3. Multikinase inhibitors

            13.2.4. Serine/Threonine Kinase Inhibitors

            13.2.5. Protein Kinase C Inhibitors

            13.2.6. RHO Kinase Inhibitors

            13.2.7. Others 

        13.3. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

            13.3.1. Oncology

                13.3.1.1. Lung Cancer

                13.3.1.2. Renal cell cancer

                13.3.1.3. Breast Cancer

                13.3.1.4. Others

            13.3.2. Inflammatory Diseases

            13.3.3. Others

        13.4. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

            13.4.1. Hospital Pharmacies

            13.4.2. Independent Pharmacies

            13.4.3. Online Pharmacies

        13.5. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Latin America Kinase Inhibitors Market Attractiveness Analysis

            13.6.1. By Type

            13.6.2. By Application

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

        14.1. Introduction

        14.2. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

            14.2.1. Non-receptor Tyrosine Kinase Inhibitors

                14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors

                14.2.1.2. BCR-ABL

                14.2.1.3. Janus Kinase (JAK) Inhibitor

                14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

                14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

                14.2.1.6. Others

            14.2.2. Receptor Tyrosine Kinase Inhibitors

                14.2.2.1. VEGFR

                14.2.2.2. PDGFR

                14.2.2.3. EGFR

                14.2.2.4. ALK

                14.2.2.5. HER2

                14.2.2.6. Others

            14.2.3. Multikinase inhibitors

            14.2.4. Serine/Threonine Kinase Inhibitors

            14.2.5. Protein Kinase C Inhibitors

            14.2.6. RHO Kinase Inhibitors

            14.2.7. Others 

        14.3. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

            14.3.1. Oncology

                14.3.1.1. Lung Cancer

                14.3.1.2. Renal cell cancer

                14.3.1.3. Breast Cancer

                14.3.1.4. Others

            14.3.2. Inflammatory Diseases

            14.3.3. Others

        14.4. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

            14.4.1. Hospital Pharmacies

            14.4.2. Independent Pharmacies

            14.4.3. Online Pharmacies

        14.5. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Israel

            14.5.4. Rest of Middle East & Africa

        14.6. Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis

            14.6.1. By Type

            14.6.2. By Application

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Competition Matrix

        15.2. Market Share Analysis, by Company (2018)

        15.3. Company Profiles

            15.3.1. Boehringer Ingelheim International GmbH

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Company Financials

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. Novartis AG 

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Company Financials

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. AstraZeneca plc 

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Company Financials

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. Pfizer, Inc. 

                15.3.4.1. Company Overview (HQ, Business Segments)

                15.3.4.2. Company Financials

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. F. Hoffmann-La Roche Ltd

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Company Financials

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. Bristol-Myers Squibb Company

                15.3.6.1. Company Overview (HQ, Business Segments)

                15.3.6.2. Company Financials

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis

            15.3.7. Johnson & Johnson 

                15.3.7.1. Company Overview (HQ, Business Segments)

                15.3.7.2. Company Financials

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. Bayer AG

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Company Financials

                15.3.8.3. Growth Strategies

                15.3.8.4. SWOT Analysis

            15.3.9. Eisai Co., Ltd. 

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Company Financials

                15.3.9.3. Growth Strategies

                15.3.9.4. SWOT Analysis

    List of Tables

    Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

    Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

    Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

    Table 04: Global Other Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

    Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)

    Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)

    Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)

    Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)

    Table 09: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 10: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 11: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 12: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 13: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

    Table 14: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 15: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 17: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 18: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 19: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 20: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

    Table 21: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 22: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 25: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 26: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 27: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

    Table 28: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 29: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 33: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 34: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

    Table 35: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 36: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 41: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

    Table 42: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 43: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

    Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

    Table 49: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 50: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figures

    Figure 01: Global Kinase Inhibitors Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

    Figure 02: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, 2017–2027

    Figure 03: Clinical Trial Analysis, by Phase

    Figure 04: Clinical Trial Analysis, by Status

    Figure 05: Global Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

    Figure 06: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

    Figure 07: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

    Figure 08: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Multikinase inhibitors, 2017–2027

    Figure 09: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Serine/Threonine Kinase Inhibitors, 2017–2027

    Figure 10: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Protein Kinase C Inhibitors, 2017–2027

    Figure 11: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by RHO Kinase Inhibitors, 2017–2027

    Figure 12: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027

    Figure 13: Global Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

    Figure 14: Global Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

    Figure 15: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oncology, 2017–2027

    Figure 16: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Inflammatory Diseases, 2017–2027

    Figure 17: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2027

    Figure 18: Global Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

    Figure 19: Global Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 20: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2017–2027

    Figure 21: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2017–2027

    Figure 22: Global Kinase Inhibitors Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2017–2027

    Figure 23: Global Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 24: Global Kinase Inhibitors Market Value Share Analysis, by Region, 2018 and 2027

    Figure 25: Global Kinase Inhibitors Market Attractiveness Analysis, by Region, 2019–2027

    Figure 26: North America Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 27: North America Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

    Figure 28: North America Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

    Figure 29: North America Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

    Figure 30: North America Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

    Figure 31: North America Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 32: North America Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 33: North America Kinase Inhibitors Market Value Share Analysis, by Country, 2018 and 2027

    Figure 34: North America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2019–2027

    Figure 35: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 36: Europe Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

    Figure 37: Europe Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

    Figure 38: Europe Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

    Figure 39: Europe Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

    Figure 40: Europe Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 41: Europe Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 42: Europe Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 43: Europe Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 44: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 45: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

    Figure 46: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

    Figure 47: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

    Figure 48: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

    Figure 49: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 50: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 51: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 52: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 53: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 54: Latin America Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

    Figure 55: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

    Figure 56: Latin America Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

    Figure 57: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

    Figure 58: Latin America Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 59: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 60: Latin America Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 61: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 62: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 63: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Type, 2018 and 2027

    Figure 64: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Type, 2019–2027

    Figure 65: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Application, 2018 and 2027

    Figure 66: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Application, 2019–2027

    Figure 67: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 68: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 69: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 70: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 71: Global Kinase Inhibitors Market Share, by Company, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved